返回 
加入收藏
广东联盟中成药集采品种质量评价标准研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 广东联盟中成药集采品种质量评价标准研究 |
| TITLE： | Study on evaluation criteria for the quality of Chinese patent medicine purchased centrally by the Guangdong alliance |
| 摘要： | 广东联盟中成药国家药品集中带量采购（简称“集采”）工作启动以来，中成药生产企业为获得中选资格展开了激烈的价格竞争。为确保集采品种“降价不降质”，本研究基于中医药的自身特点，构建了一套中成药质量评价标准。评价体系包含生产过程和药效评估2个一级维度，指标设置覆盖中成药从原料选材到生产加工，再到临床使用全生命周期。生产过程维度包含3个二级维度（中药材质量、中药饮片质量和中成药质量）和13个三级指标（规范化生产、质量检验、炮制规范、技术工艺、安全风险控制等），能全面反映中成药生产关键环节的质量控制；药效评估维度包含5个二级维度（组方理论渊源、生产企业主动研究、循证医学证据、临床使用情况和科技体现）和18个三级指标（理论来源、上市后有效性再评价、临床指南、专家共识等），从多角度、多层次考察中成药的质量与疗效。本研究是对广东联盟中成药集采方案的有益补充，不仅能为“低价优质”的中成药品种筛选提供数据支撑，也能为医疗机构制定集采决策提供参考。 |
| ABSTRACT： | Since the Guangdong alliance launched the centralized procurement of Chinese patent medicine， manufacturers have engaged in fierce price competition to obtain the qualification for selection. In order to ensure that manufacturers have lowered the price without decreasing quality， the evaluation criteria for the quality of Chinese patent medicine is constructed on the basis of the characteristics of traditional Chinese medicine. The evaluation criteria consist of the production process and therapeutic effect evaluation. The evaluation indicators involve raw materials， processing and clinical use covering the whole life cycle of Chinese patent medicine. The evaluation of production process includes 3 secondary indicators （the quality of traditional Chinese medicine， the quality of traditional Chinese medicine decoction pieces and the quality of Chinese patent medicines） and 13 tertiary indicators （standardized production， quality inspection， processing specifications， technical processes， safety risk control， etc.）， which fully reflect the quality control of key links in the production of Chinese patent medicine. The therapeutic effect evaluation includes 5 secondary indicators （theoretical origin of formulation， proactive research by production enterprises， evidence-based medical evidence， clinical use， and technological embodiment） and 18 tertiary indicators （theoretical sources， post-market effectiveness re- evaluation， clinical guidelines， expert consensus， etc.） to assess the quality and efficacy of Chinese patent medicine from multiple perspectives and levels. This study is a useful supplement to the scheme of centralized procurement of Guangdong alliance， which can not only provide data support for selecting “low-cost and high-quality” Chinese patent medicine， but also provide information reference for hospitals to make procurement decisions. |
| 期刊： | 2023年第34卷第17期 |
| 作者： | 陈举亮；张慧；林慧芸；胡紫微 |
| AUTHORS： | CHEN Juliang，ZHANG Hui，LIN Huiyun，HU Ziwei |
| 关键字： | 中成药；集中带量采购；质量评价；质量控制；疗效 |
| KEYWORDS： | Chinese patent medicine； centralized procurement； quality evaluation； quality control； therapeutic effect |
| 阅读数： | 81 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
